<- Go home

Added to YB: 2026-03-17

Pitch date: 2026-03-14

CPH.TO [neutral]

Cipher Pharmaceuticals Inc.

-2.02%

current return

Author Info

Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 267.6M

Pitch Price

CAD 16.80

Price Target

N/A

Dividend

N/A

EV/EBITDA

11.19

P/E

10.08

EV/Sales

5.27

Sector

Pharmaceuticals

Category

growth

Show full summary:
Cipher Pharmaceuticals Q4 2025 Update – $CPH.TO

CPH.TO (earnings): Q4 rev $12.2M (+3%), FY25 rev $50.5M (+51%), adj EBITDA $28.1M (+79%). Natroba drove growth: $30M rev, 83% gross margin, 60% of total rev. Paid off $35M debt in 18mo, $5M remains. DTC platform, Canada launch (late 2026), global licensing to expand Natroba. M&A remains priority. 11x EV/EBITDA, 10-11x FCF. Absorica royalty ends 2025.

Read full article (3 min)